GlassScriptPhysician profile
Mary Donovan
NPI 1558630533
$1,269.86
in general payments reported to CMS, 2019-2025
20 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $177 · 2023: $232 · 2024: $541 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $213.15 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $175.84 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $119.14 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $109.42 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $101.47 | 2024 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $67.52 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Dexcom, INC. | $62.75 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $52.14 | 2023-2025 | |
| Glaxosmithkline, LLC. | $51.19 | 2023-2024 | Shingrix, Arexvy |
| Abbvie INC. | $50.97 | 2022-2024 | |
| Abbott Laboratories | $47.64 | 2022-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.76 | 2024-2025 | Jardiance |
| Currax Pharmaceuticals LLC | $31.85 | 2023 | Contrave |
| Corium, LLC | $30.09 | 2023 | Azstarys |
| Phathom Pharmaceuticals, INC. | $25.02 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.31 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $22.86 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $17.24 | 2022 | |
| Astellas Pharma US INC | $16.84 | 2024 | Veozah |
| Harmony Biosciences LLC | $14.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.